FDA Cleared a New Once-Daily Psoriasis Pill. What That Means for People With Moderate to Severe Plaque Psoriasis

The FDA has approved Icotyde, the brand name for icotrokinra, as a new once-daily pill for certain people with moderate to severe plaque psoriasis. The March 17, 2026 approval applies to adults and adolescents age 12 and older who weigh at least 40 kilograms, or about 88 pounds, and who are candidates for systemic therapy or phototherapy.

That last part matters. This is not a treatment for every case of psoriasis, and it is not meant for mild disease that can be managed with creams alone. It is an option for people whose psoriasis is serious enough that they may need whole-body treatment, such as pills, shots, or supervised light therapy.

Why a once-daily pill stands out

Plaque psoriasis can be painful, itchy, visible, and exhausting to live with. The World Health Organization has noted that psoriasis affects far more than appearance. It can affect quality of life, mental well-being, work, and social life, and it can carry stigma for both adults and teens.

Many effective psoriasis treatments already exist, including biologic injections, older oral drugs, and phototherapy. What makes icotrokinra different is that it is a targeted oral medicine taken once a day. The FDA label describes it as an interleukin-23, or IL-23, receptor antagonist. In plain language, it blocks a specific immune pathway involved in psoriasis inflammation.

For some patients, that could be appealing because it offers a targeted treatment without injections. But convenience is not the same as being the best choice for everyone. Treatment decisions still depend on how severe the disease is, what other health conditions a person has, past treatment response, side effects, pregnancy considerations, and what insurance will actually cover.

Who may be eligible

Under the FDA approval, Icotyde is for adults and teens 12 and older who weigh at least 40 kilograms and are candidates for systemic therapy or phototherapy. In everyday terms, that usually means psoriasis is widespread, has not responded well enough to topical treatment, affects sensitive or high-impact areas, or is interfering with daily life enough that a stronger treatment approach is reasonable.

American Academy of Dermatology guidance reinforces that psoriasis treatment is individualized. Depending on the patient, options may include phototherapy, oral nonbiologic drugs, biologics, or other systemic treatments. A newly approved pill adds another choice, but it does not replace the need for a personalized treatment plan.

What the trials actually showed

The approval rests on phase 3 randomized evidence, including a double-blind, placebo-controlled trial published in a major medical journal and summarized in the FDA label.

In the mixed adult-adolescent trial used for the label, 684 people with moderate to severe plaque psoriasis were randomized to icotrokinra or placebo for 16 weeks. That study included 66 adolescents. By week 16, 50% of people taking icotrokinra reached PASI 90, which means at least a 90% improvement in psoriasis severity, compared with 4% on placebo. Also by week 16, 65% of the icotrokinra group reached an Investigator’s Global Assessment result of clear or almost clear skin, compared with 8% on placebo.

Those are meaningful short-term results. They suggest that many patients saw major improvement within four months. But there are also limits to what these studies can tell us. The main approval-defining results were against placebo, not against injectable biologics. So this approval does not prove that icotrokinra is better than the leading biologic shots, or that it will be the right first choice for every patient.

Two separate adult phase 3 trials also included secondary comparisons with deucravacitinib, another oral psoriasis medicine. In those trials, week 16 PASI 90 response rates were higher with icotrokinra than with deucravacitinib. That is useful information, but these were secondary comparisons, not the core placebo-controlled endpoints that mainly supported approval. They also do not settle broader questions about long-term real-world performance or how the new pill compares with injectable biologics.

What the teen data showed

The pediatric part of the approval is important because treatment options can feel more limited for families with adolescents who have moderate to severe disease.

The FDA label includes a pediatric subgroup from the phase 3 program. Among teens ages 12 to 17 in that subgroup, 84% of those assigned to icotrokinra reached clear or almost clear skin at week 16, compared with 27% on placebo. For PASI 90, the figures were 70% with icotrokinra and 14% with placebo.

Those numbers are encouraging, but they should be read with caution. The pediatric subgroup was small, with 44 teens in the icotrokinra group and 22 in the placebo group. Small subgroups can still be informative, but they leave more uncertainty than larger studies do.

How to take it

According to the FDA label, the recommended dose is 200 milligrams by mouth once daily. It should be taken upon waking on an empty stomach with water, and the patient should wait at least 30 minutes before eating.

That may sound minor, but timing rules can affect how easy a medication is to use in everyday life, especially for teens getting ready for school or adults juggling work and family routines.

Safety points to know before asking about it

Because icotrokinra affects the immune system, infection precautions matter.

The FDA label says treatment should be avoided in patients with a clinically important active infection until that infection has resolved or been adequately treated. The label also says clinicians should consider evaluating patients for tuberculosis before starting treatment, based on clinical judgment, and avoid use in patients with active TB. Live vaccines should be avoided during treatment.

The most common side effects listed in the prescribing information were headache, nausea, cough, fungal infection, and fatigue.

That does not mean everyone will have side effects, and it does not mean the drug is broadly proven safer than biologic therapies overall. It means the early safety profile in the approval studies looked acceptable enough for approval, while still calling for the usual caution around infections and vaccine timing.

Where this fits in psoriasis care now

For some patients, a once-daily targeted pill may be easier to accept than an injection or infusion. For others, an existing biologic, an older oral drug, or phototherapy may still make more sense. Some people may prioritize convenience. Others may prioritize long-term familiarity, insurance coverage, or a treatment they already know works for them.

It is also worth remembering that plaque psoriasis is a chronic disease with no cure. A newly approved medicine can improve symptoms and help many patients reach much clearer skin, but it does not erase the need for ongoing care, monitoring, and reassessment over time.

The access question may be the hardest one

The FDA approval answers whether the drug can be prescribed. It does not answer whether a patient’s health plan will cover it quickly, what the copay will be, or whether prior authorization will be required.

That is often the next real hurdle with a newly approved specialty medicine. Families and patients may need to ask whether the drug is on their plan’s formulary, whether step edits or prior authorization apply, and what out-of-pocket costs would look like before getting too far into the decision.

In other words, the existence of a new psoriasis pill is important. Actual access may still depend on insurance rules as much as on the science.

What this means for readers

If you or your child has moderate to severe plaque psoriasis and wants to avoid injections, Icotyde may be worth asking a dermatologist about. The short-term trial results were strong, especially compared with placebo, and the once-daily oral format will matter to many people.

But it is not a cure, not a treatment for mild psoriasis, and not automatically the best first choice for everyone. Before starting, it makes sense to discuss infection history, TB risk, vaccine timing, side effects, and whether your insurance is likely to cover the medication.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.